Blog

Home  >  Resources  >  Blog

When we are dealing with code level data, important basics include the billing of the correct units and making sure that you are billing under the correct code. For this year, seven brands of quadrivalent vaccines are available, but due to different properties including dose, 28 individual NDCs crosswalked back to 9 different codes.   This […]

INSIDE THIS ISSUE Code Updates: Update -J-Code 1599 Addition of 12 active NDCs Update- Removal of minimum and maximum dosing for J1325 and J3285 Update- Revision of maximum dose for J2278  CMS News: Medicare Influenza Vaccine Pricing 2018-2019 Season NEW Influenza CPT® Code 90689 Effective January 1, 2019 NEW HCPCS® Codes and Changed Code Descriptions […]

Hello. I am Wendy Sullivan, Director of Drug Informatics for RJ Health. I’d like to welcome you to today’s webinar-Creating Pre-Payment Controls for Medically Covered Drug Costs through Automation. Before we get started, I’d like to thank you for attending and to thank my colleagues who helped make this webinar possible. In terms of my […]

New Drug Overview – levoleucovorin (Khapzory™) On October 19, 2018, the U.S. Food and Drug Administration (FDA) approved levoleucovorin (Khapzory™) for three indications. Rescue after high-dose methotrexate therapy in patients with osteosarcoma. Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination. The treatment of patients with metastatic colorectal cancer in […]

Over the last five years we have mapped over 520 vaccine NDCs to over to over 130 vaccine billing codes. Several of these codes cover just this year’s flu vaccines alone. Codes for flu vaccines are updated every year due to new code approval process: This segment is from RJ Health’s On-Demand Webinar: Vaccine Coding Challenges […]

In October there were a total of seven new drug approvals by the FDA we deemed specific to the specialty market. One of these approvals was for a biosimilar of Humira, which due to patents, is not slated to be launched until 2023. In addition, there were five supplemental drug approvals, two of which were […]

  Below is the transcript from our On-Demand Micro-Webinar: Vaccine Coding Challenges Powered by ReimbursementCodes.com Laura:    Good day, welcome, and thanks for joining us. Today we’d like to help you by providing a quick brush up on vaccine coding. I’m Laura, Clinical Informatics Pharmacist for RJ Health, and joining me today is Chris Webb who is our […]

Last week a portion of the RJ Health team left our corporate headquarters to help with the Dog Days Adoption Intake Day, in preparation for the Dog Days Adoption Event that was held the weekend of October 20 – 21. Our day began with the highly anticipated arrival of the puppy transport.  The crew of […]

FDA Approval: 10/5/2018 Familial amyloid polyneuropathy (FAP, also called transthyretin amyloidosis) is a hereditary neurodegenerative disease that is characterized by the accumulation and deposition of the transthyretin protein (TTR) in the tissues and peripheral nervous system, and often causes pain, muscle weakness, and autonomic dysfunction. Eventually, the disease progresses into a sensory and motor polyneuropathy. […]

New Drug Overview – elapegademase-lvlr (Revcovi™) On October 5, 2018, the U.S. Food and Drug Administration (FDA) approved elapegademase-lvlr (Revcovi™) for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.  (ADA-SCID) is a rare genetic disorder that primarily affects infants and young children and is fatal if left untreated. […]